In the general news, Russia seems to be edging toward a war with NATO and the U.S. by sending troops into sovereign Ukraine. In the States, the stock markets finish up 5% for the month, offsetting January losses. Meanwhile, the record cold winter continues, hurting the economy.
In healthcare business news, Endologix (ELGX) stock sank 25% on bad revenue guidance for its AAA stent graft. Medivation (MDVN) also sank on lowered revenue guidance for prostate cancer drug Xtandi drug. Elsewhere, Eli Lilly (LLY) acquired Lohmann for animal health, and Bayer acquired Dihon for its traditional herbal Chinese medication products.
On the data front, InterMune (ITMN) spiked 155% on new clinical data for pirfenidone to treat treating idiopathic pulmonary fibrosis (IPF). Previous studies failed. Also, the CDC updated the obesity study, reporting that the epidemic of obesity is waning.
From the FDA, Anika Therapeutics’ (ANIK) received approval for arthritis therapy Monovisc. Bristol-Myers Squibb (BMY) won approval for Myalept to treat generalized lipodystrophy. Also, Dexcom (DXCM) won approval for the G4 PLATINUM (Pediatric) Continuous Glucose Monitoring System.